For adults on maximally tolerated statins with TG ≥150 mg/dL and established CVD or diabetes and ≥2 CVD risk factors

Unprecedented CV risk reduction in broad patient populations1

Approximately every 40 seconds, someone will experience an MI or Stroke, or die from CVD in the United States. And the prevalence of heart disease in both men and women is only expected to grow.2-4 But, who is at risk?

According to a 2008 trial, patients with TG levels ≥150 mg/dL have a 41% higher risk of suffering from coronary events* than those with TG <150, despite achieving LDL-C <70 mg/dL.5 This indicates that elevated TG, similar to high LDL-C, is a critical risk factor for Persistent CV Risk (P-CVR). However, TG-lowering agents have failed to show CV risk reduction, proving that more strategies to reduce P-CVR are needed.6-10

Not an actual VASCEPA patient.

David, 65

  • Established CVD (CAD & history of MI)
  • On statin therapy
  • TG: 185 mg/dL

Reason for visit: Routine office visit

Clinical CVD diagnosis:

  • MI & stents placed at 57 yrs. old
  • CAD & hypertension
  • History of high cholesterol

Family history:

  • CVD, father died from MI at 68 yrs. old

Diagnostics:

  • LDL-C: 68 mg/dL
  • TG: 185 mg/dL
  • HDL-C: 42 mg/dL
  • BP: 138/82 mm Hg
  • BMI: 34

Medications:

Atorvastatin 80 mg, irbesartan, clopidogrel, ASA, and metoprolol

VASCEPA can help patients like David

See how

Not an actual VASCEPA patient.

Donna, 55

  • T2D, hypertension, and high cholesterol
  • On statin therapy
  • TG: 150 mg/dL

Reason for visit: Younger friend had a CV event; wants to check on her health

Clinical CVD diagnosis:

  • T2D at 42 yrs. old
  • Hypertension
  • High cholesterol

Family history:

  • Mother had CVD; father had hypertension

Diagnostics:

  • LDL-C: 84 mg/dL
  • TG: 150 mg/dL
  • HDL-C: 58 mg/dL
  • BP: 142/82 mm Hg
  • BMI: 31
  • HbA1c: 7.9

Medications:

Rosuvastatin 10 mg, metformin, lisinopril, amlodipine, and pantoprazole

VASCEPA can help patients like Donna

See how

Not an actual VASCEPA patient.

James, 46

  • Established CVD and T2D
  • On statin therapy
  • TG: 320 mg/dL

Reason for visit: Approaching the age that his father had an MI

Clinical CVD diagnosis:

  • T2D at age 32 yrs. old
  • High cholesterol
  • PAD
  • Smoker

Family history:

  • Extensive family history of CV disease

Diagnostics:

  • LDL-C: 95 mg/dL
  • TG: 320 mg/dL
  • HDL-C: 40 mg/dL
  • BP: 135/84 mm Hg
  • BMI: 30
  • HbA1c: 8.3

Medications:

Rosuvastatin 10 mg, clopidogrel, ASA, metoprolol, insulin, and sitagliptin and metformin HCl

VASCEPA can help patients like James

See how

This site uses cookies to give you the best possible experience. By browsing our website, you agree to our use of cookies. If you require further information and/or do not wish to have cookies placed when using the site, visit the Privacy Policy page.

Exit

IMPORTANT SAFETY INFORMATION

VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components

VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter

It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur

INDICATIONS AND LIMITATIONS OF USE

VASCEPA® (icosapent ethyl) is indicated as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease

VASCEPA is indicated as an adjunct to diet to reduce TG levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia

The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.

VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin

Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%) and atrial fibrillation (5% vs 4%)

Common adverse reactions in the hypertriglyceridemia trials (incidence ≥1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%)

Adverse Events, Product Complaints, or Special Situations may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088

Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding

Please see full Prescribing Information for more information on VASCEPA.

CAD=coronary artery disease; eCVD=established cardiovascular disease; MI=myocardial infarction; PAD=peripheral arterial disease; T2D=type 2 diabetes.
*Death, MI, or recurrent acute coronary syndrome.

References: 1. VASCEPA [package insert]. Bridgewater, NJ: Amarin Pharma, Inc.; 2019. 2. Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528. 3. Centers for Disease Control and Prevention. Heart disease facts. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_heart_disease.htm. Accessed March 24, 2020. 4. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf. Accessed March 24, 2020. 5. Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; for the PROVE IT-TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51(7):724-730. 6. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, et al. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309-318. 7. Risk and Prevention Study Collaborative Group. n–3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800-1808. 8. Rauch B, Schiele R, Schneider S, et al; for the OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152-2159. 9. ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540-1550. 10. Manson JE, Cook NR, Lee IM, et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380(1):33-44.